Peptide classifier for IgAN disease progression

The proteomics IgAN237 diagnostic test was develop within the PersTIgAN project for prediction of fast progressive IgA Nephropathy (IgAN), to guide immunosuppressive intervention. This test is based on 237 urinary biomarkers significantly associated with disease progression. To obtain the IgAN237 proteomics score the urine sample has to be analysed by mosaiques diagnostics GmbH by capillary electrophoresis coupled mass spectrometry.

For optimal results, the IgAN237 score has to be adjusted for relevant baseline clinical variables. This based on results from PersTIgAN project, where the adjustment of IgAN237 for baseline clinical data improved the prediction of progressive IgAN and the relevance of the result in the prediction of response to immunosuppression.


Baseline clinical data required for IgAN237 proteomics score adjustment are:

  • Age
  • Glomerula filtration rate (eGFR) in ml/min/1.73m2, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
  • Mean arterial pressure (MAP) in mmHG, MAP= ((2xdiastiolic blood pressure) + systolic blood pressure) / 3
  • Sex (female=0, male=1)
  • Urine protein in g/day

Calculate your adjusted IgAN237 proteomics score:

Interpretation of IgAN237 adjusted proteomics score:

A IgAN237 sore below 0.23 indicates slow progressive (stable) IgAN. A score above 0.71 indicates progressive IgAN. A The higher the current score and the larger the distance from diagnosis threshold (0.48), the higher the confidence in the prediction of future development.

The threshold for the adjusted IgAN237 proteomics score was defined within the PersTIgAN project as 0.48. In addition, a borderline range (+ 1 SD) was defined based on the mean standard deviation of 0.25 within the PersTIgAN project.